STRO News and Press, Sutro Biopharma Inc. From 11/27/23

-- Vaxcyte Obtains Exclusive Rights to Independently Develop and Manufacture Cell-Free Extract, a Key Component of the Company’s Pneumococcal Conjugate Vaccine (PCV) Franchise -- -- Manufacturing Rights Agreement Further Strengthens Vaxcyte’s Long-Term, Global Commercial M...

2023-11-21 16:09:06 ET More on Sutro Biopharma Sutro Biopharma: Luvelta Data For Endometrial Cancer Treatment Approaching Sutro BioPharma: Good Stewardship Through Early Trials For further details see: Sutro Biopharma appoints Chung as its COO

SOUTH SAN FRANCISCO, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the promotion of Jane Chung to President and Chi...

2023-11-14 10:04:00 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stocks to watch in the Health Care sector a...

Sutro Biopharma Inc. (STRO) is expected to report $-0.76 for Q3 2023

2023-11-13 17:41:08 ET More on Sutro Biopharma Sutro Biopharma: Luvelta Data For Endometrial Cancer Treatment Approaching Sutro BioPharma: Good Stewardship Through Early Trials For further details see: Sutro Biopharma GAAP EPS of -$0.81, revenue of $16.9M

2023-11-13 17:36:19 ET More on Sutro Biopharma Sutro Biopharma: Luvelta Data For Endometrial Cancer Treatment Approaching Sutro BioPharma: Good Stewardship Through Early Trials Sutro gains as Oppenheimer sees 200% upside on ADC potential Seeking Alpha’...

- Updated luvelta data from Compassionate Use Access demonstrating anti-leukemic activity in pediatric patients with relapsed/refractory CBF2AT3-GLIS2 AML to be presented in a poster at ASH 2023 - - Luvelta demonstrated encouraging preliminary anti-tumor activity in initial data from th...

- Luvelta demonstrate d encouraging preliminary anti-tumor activity (29% response rate) in late-stage patients with recurrent/relapsed endometrial cancer with tumor proportion score (TPS) >25% FolRα expression – - Safety profile was consistent with prior data ...

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that the company will have five presentations an...